🚨 Scientists have engineered a common probiotic to act as a cancer-seeking 'drug factory,' completely eradicating 43% of colorectal tumors in preclinical trials.
The study, led by researchers at Columbia University, utilized a modified strain of Escherichia coli Nissle 1917, a safe gut microbe.
Because tumors provide an oxygen-low, nutrient-rich environment where the immune system is suppressed, the injected bacteria naturally migrate to and multiply inside the cancerous cells.
Once established, these engineered microbes act as tiny localized drug factories, converting a separately administered, non-toxic compound into a potent chemotherapy drug directly at the tumor site, minimizing damage to surrounding healthy tissue.
To maximize effectiveness, the probiotic was also engineered to deliver a powerful dual-action immune boost. It releases an immune-stimulating protein to recruit the body's natural defenses, alongside a specialized nanobody that unmasks cancer cells, preventing them from hiding from the immune system.
This 'triple-whammy' therapy—combining localized chemo, immune stimulation, and immune checkpoint blockade—completely eliminated established colorectal tumors in 43% of treated cases in preclinical trials.
By proving that living medicines can reprogram tumor microenvironments, this breakthrough offers a promising, highly precise alternative to conventional, high-toxicity treatments.
source: Yang, Z., Im, J., Chen, N., Mariuzza, D. L., de los Santos-Alexis, K., Li, F., Ballister, E. R., Ringham, O. R., Danino, T., & Arpaia, N. (2026). Engineered probiotics for tumor-targeted combination chemoimmunotherapy. Science Translational Medicine, 18(867), eady2289.